people at high risk of pneumococcal disease, an infection that causes pneumonia—children younger than 2, adults older than 64, and those with certain chronic health conditions such as diabetes ...

The Centers for Disease Control and Prevention changed the recommended age for getting the vaccine for pneumococcal pneumonia from those 65 and older to those 50 and above. Fifty is also the age when ...

Officials also recommend the shots for children and adults at increased risk for pneumococcal disease, such as those with ...

The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.

With Capvaxive, MSD (known as Merck & Co in the US and Canada) is aiming to carve out a niche in the over-50s, positioning it as the go-to vaccine used to prevent invasive pneumococcal disease ...

Vaccination and HIV treatment reduce the risk of invasive pneumococcal disease. Pneumococcal disease is treated with antibiotics. Pneumococcal disease is caused by a bacterium called Streptococcus ...

Pneumococcal vaccine polyvalent ... efficacy was 65–84% among specific patients groups (eg, diabetes mellitus, coronary vascular disease, congestive heart failure, chronic pulmonary disease ...

There are around 100 different pneumococcal serotypes, causing non-invasive disease like pneumonia, confined to the lungs, and invasive disease, where the infection can spread to the bloodstream ...

The active substance of Capvaxive works by triggering an immune response against 21 serotypes that cause most invasive pneumococcal disease cases. At its January meeting, the EMA’s Committee for ...

Pneumococcal pneumonia is a type of lung ... Fifty is also the age when the risk for comorbidities — conditions like diabetes, heart disease and chronic obstructive pulmonary disease — increases.